FibroMeter scores for the assessment of liver fibrosis in patients with autoimmune liver diseases
Autore
Zachou K., Lygoura V., Arvaniti P., Giannoulis G., Gatselis N.K., Koukoulis G.K., Dalekos G.N.Data
2021Language
en
Soggetto
Abstract
Introduction and Objectives: We assessed FibroMeter virus (FMvirus) and FibroMeter vibration-controlled transient elastography (FMVCTE) in 134 patients with autoimmune liver diseases [ALD, autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC)], in order to assess new potential non-invasive biomarkers of liver fibrosis in patients with ALD, as similar data are missing. Patients and Methods: The following groups were included: group 1: n = 78 AIH; group 2: n = 56 PBC. FMvirus and FMVCTE were determined in all 134 patients who underwent liver biopsy and TE the same day with sera collection. In addition, APRI and FIB-4 scores were calculated. Results: The AUCs for TE and FMVCTE were significantly better (0.809; p < 0.001 and 0.772; p = 0.001, respectively for AIH and 0.997; p < 0.001 and 1; p < 0.001, for PBC) than the other three markers in predicting ≥ F3 fibrosis irrespective of the biochemical activity. FMVCTE and TE had good diagnostic accuracy (75.6% and 73%, respectively) for predicting severe fibrosis in AIH and performed even better in PBC (94.6% and 96.4%, respectively). The cut-offs of TE and FMVCTE had the best sensitivity and specificity in predicting ≥ F3 fibrosis in both AIH and PBC. Conclusions: FMVCTE seems to detect severe fibrosis equally to TE in patients with ALD but with better specificity. Biochemical disease activity did not seem to affect their diagnostic accuracy in ALD and therefore, could be helpful for the assessment of fibrosis, especially if they are performed sequentially (first TE with the best sensitivity and then FMVCTE with the best specificity). © 2020 Fundación Clínica Médica Sur, A.C.
Collections
Related items
Showing items related by title, author, creator and subject.
-
The challenges of primary biliary cholangitis: What is new and what needs to be done
Terziroli Beretta-Piccoli B., Mieli-Vergani G., Vergani D., Vierling J.M., Adams D., Alpini G., Banales J.M., Beuers U., Björnsson E., Bowlus C., Carbone M., Chazouillères O., Dalekos G., De Gottardi A., Harada K., Hirschfield G., Invernizzi P., Jones D., Krawitt E., Lanzavecchia A., Lian Z.-X., Ma X., Manns M., Mavilio D., Quigley E.M., Sallusto F., Shimoda S., Strazzabosco M., Swain M., Tanaka A., Trauner M., Tsuneyama K., Zigmond E., Gershwin M.E. (2019)Primary Biliary Cholangitis (PBC) is an uncommon, chronic, cholangiopathy of autoimmune origin and unknown etiology characterized by positive anti-mitochondrial autoantibodies (AMA), female preponderance and progression ... -
A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis
Zachou K., Gatselis N.K., Arvaniti P., Gabeta S., Rigopoulou E.I., Koukoulis G.K., Dalekos G.N. (2016)Background Front-line therapy with mycophenolate mofetil (MMF) in autoimmune hepatitis (AIH) has shown high on-treatment remission rates. Aim To study prospectively in a real-world fashion the long-term outcome of a large ... -
Smoking as a risk factor for autoimmune liver disease: What we can learn from primary biliary cirrhosis
Smyk, D. S.; Rigopoulou, E. I.; Muratori, L.; Burroughs, A. K.; Bogdanos, D. P. (2012)Primary biliary cirrhosis (PBC) is a cholestatic liver disease characterised by the immune-mediated destruction of biliary epithelial cells in small intrahepatic bile ducts. The disease is characterised by circulating ...